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ABSTRACT
Aims/Introduction: Measurement of glycated hemoglobin (HbA1c) has been recom-
mended for the diagnosis of diabetes and prediabetes. However, epidemiological studies
have shown significant discordance between HbA1c and glucose-based tests. Of the fac-
tors that could influence agreement between HbA1c and the oral glucose tolerance test
(OGTT), bodyweight has not been fully evaluated. The aims of the present study were to
evaluate the impact of HbA1c criteria to diagnose diabetes and prediabetes compared
with OGTT, and to examine HbA1c in relation to body mass index.
Materials and Methods: Two cohorts were studied, one from an obesity clinic
(n = 592) and one from subjects undergoing screening for diabetes (n = 462). All under-
went OGTT and HbA1c measurement.
Results: In the obese cohort, HbA1c ≥6.5% (≥48 mmol/mol) showed a sensitivity of
69.3% for diabetes, whereas HbA1c 5.7–6.4% (39–46 mmol/mol) did not identify prediabe-
tes well (sensitivity 39.1%). In the diabetes screening cohort, HbA1c had low sensitivities
for both diabetes (39.2%) and prediabetes (53.3%). When participants were stratified
according to body mass index class I–III, HbA1c agreement with the OGTT for diabetes
was much higher (80%, P < 0.005) in class I obesity compared with class II–III obesity;
whereas for prediabetes, HbA1c had a low sensitivity in all obesity classes.
Conclusions: The agreement between HbA1c, fasting plasma glucose and 2-h glucose
post-OGTT for the diagnosis of prediabetes was poor in our Italian population; whereas
HbA1c ≥6.5% showed a relatively good agreement with OGTT for the diagnosis of diabe-
tes. For the first time, we have shown that obesity class influences the diagnostic perfor-
mance of HbA1c.
INTRODUCTION
Glycated hemoglobin (HbA1c) is the gold standard for
monitoring glycemic control in patients with diabetes mellitus.
The HbA1c assay provides an accurate, precise measure of
chronic glycemic levels, and correlates with the risk of diabetes
complications. The use of this test has been extended to diag-
nose and screen for diabetes mellitus with the endorsement of
several international diabetes societies and the World Health
Organization. In 2010, the International Expert Committee and
the American Diabetes Association proposed diagnostic criteria
for diabetes and prediabetes based on HbA1c levels. These are
HbA1c ≥6.5% (≥48 mmol/mol) to diagnose diabetes mellitus
and between 5.7–6.4% (39–46 mmol/mol) for prediabetes1.Received 2 October 2013; revised 11 March 2014; accepted 2 April 2014
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Epidemiological studies have shown significant discordance
between HbA1c and glucose-based tests for defining diabetes
and prediabetes. For the diagnosis of diabetes, HbA1c showed
24% sensitivity and 99% specificity in the Dutch population2.
These levels of sensitivity and specificity were replicated in sev-
eral other studies3–7, all suggesting poor agreement between
HbA1c, fasting plasma glucose (FPG) and 2-h plasma glucose
(2 hPG).
Furthermore, the degree of diagnostic agreement of HbA1c
criteria with the fasting and 2 h glucose-based criteria for
prediabetes was also questioned8,9, and might be different
across ethnic groups and populations10, thus suggesting that
the diagnostic performance of HbA1c will depend also on
the target population. In a study by Mann et al.8, for
example, prediabetes by the HbA1c criterion showed 27%
sensitivity and 93% specificity, with 61% positive predictive
value, a result confirmed by Heinaza et al.9, where a
threshold of HbA1c 5.7% again showed low sensitivity (24%)
with high specificity (91%), whereas HbA1c of 5.5% gave the
highest combination of specificity (76%) and sensitivity
(46%).
Obesity is one of the major risk factors for diabetes and
impaired glucose regulation11, and has reached epidemic
proportions. It might be postulated that in obese subjects, at
increased risk for glucose abnormalities, the efficacy of
HbA1c could be higher than in normal weight people, and
therefore of increased clinical utility. One recent study has
shown a modest increased risk of prediabetes associated with
obesity12. However, to our knowledge, no studies have
explored the impact of different grades of obesity (class I–III)
on the efficacy of HbA1c to diagnose diabetes and
prediabetes.
Furthermore, as several studies have shown a large propor-
tion of patients that are discordantly categorized by HbA1c or
OGTT, their phenotypic characterization needs to be assessed,
in order to identify those parameters that could be of help in
the choice of the most appropriate diagnostic tests.
Finally, only one study13 so far has analyzed the relationship
between HbA1c and plasma glucose values for the diagnosis of
prediabetes in the Italian population, showing again poor
agreement between HbA1c and FPG.
Hence, the aims of the present study were to evaluate the
impact of HbA1c criteria to diagnose diabetes and prediabetes
in two large cohorts of participants undergoing OGTT, one
recruited from an obesity clinic and one from a cohort
undergoing screening for diabetes. Then, we aimed to investi-
gate whether differences exist between obesity classes I–III with
respect to the relationship of HbA1c and blood glucose. Finally,
we examined the phenotypic characteristics of those
participants who had a diagnosis of prediabetes with the
OGTT, but had a normal HbA1c, comparing them with those
that were concordant with both tests, aiming to identify specific
clinical variables that might help to direct the choice of the
most appropriate diagnostic test.
MATERIALS AND METHODS
Participants and Measurements
A total of 1,054 Caucasian Italian participants (mean age
48.8 – 14.4 years) were selected. Of these, 592 were recruited
from the Obesity Outpatient Clinic of the Endocrinology Unit,
Department of Clinical Sciences, Sapienza University of Rome,
Rome, Italy. These participants were referred for a complete
evaluation of their excess weight, and undertook a medical and
laboratory evaluation. The other 462 participants were recruited
from patients undergoing a screening for diabetes at the Endo-
crinology and Diabetes Unit, Department of Medical Sciences,
University of Cagliari, Cagliari, Italy. These participants had the
indication from their GPs to screen for diabetes owing to the
presence of risk factors, such as obesity, hypertension, dyslipide-
mia and diabetes in first-degree relatives. All 1,054 participants
underwent a standard oral glucose tolerance test (OGTT).
For all patients, whole blood and serum samples were col-
lected for measurement of HbA1c and serum glucose concen-
trations, respectively. Each method was carried out according to
the 2013 American Diabetes Association recommendations1.
Serum glucose concentrations were measured by an automated
enzymatic ultraviolet method, glucose-6-phosphate dehydroge-
nase/hexokinase, using a Miura 200 Chemistry analyzer (I.S.E.
SRL, Rome, Italy). HbA1c was measured using a G8 analyzer
(THOSO Diagnostics, Tokyo, Japan) by high-performance
liquid chromatography, aligned with International Federation of
Clinical Chemistry standardization, according to Diabetes Con-
trol and Complications Trial/Uniter Kingdom Prospective Dia-
betes guidelines.
Glucose tolerance status was assessed by the 75-g OGTT. In all
participants, diagnosis of type 2 diabetes was based on either fast-
ing plasma glucose ≥7.0 mmol/L (126 mg/dL) or plasma glucose
≥11.1 mmol/L (200 mg/dL) 2 h after the 75-g glucose load.
Diagnosis of prediabetes was based on a fasting plasma glucose
≥5.6 mmol/L (100 mg/dL impaired fasting glucose [IFG]) or
plasma glucose between 7.8–11.05 mmol/L (140–199 mg/dL
impaired glucose tolerance [IGT]) 2 h after the OGTT.
For the entire cohort, after the OGTT, 0 min and 120 min
insulin levels, body mass index (BMI) and blood pressure were
recorded. For the subset of 592 patients from the obesity clinic,
we also collected data regarding lipids (total cholesterol, high-
density lipoprotein cholesterol, low-density lipoprotein choles-
terol and triglycerides), aspartate aminotransferase and alanine
aminotransferase by standard laboratory methods. For the
majority of patients, it was also possible to assess the presence
or absence of lipid-lowering or antihypertensive therapy. Partic-
ipants were considered dyslipidemic if presenting high lipid
levels according to National Cholesterol Education Program –
Adult Treatment Panel III14 and/or were treated with lipid-
lowering agents, and the diagnosis of hypertension was based
on the presence of elevated systolic (>140 mmHg) and/or
diastolic (>90 mmHg) blood pressure, and/or the current use
of antihypertensive medications.
ª 2014 The Authors. Journal of Diabetes Investigation published by AASD and Wiley Publishing Asia Pty Ltd J Diabetes Invest Vol. 6 No. 1 January 2015 45
O R I G I N A L A R T I C L E
http://onlinelibrary.wiley.com/journal/jdi HbA1c and diagnosis of diabetes and prediabetes
The present study was reviewed and approved by the Ethics
Committee of Policlinico Umberto I, Sapienza University of
Rome and carried out in conformance with the Helsinki Decla-
ration. Written consent was obtained from all patients before
the study.
Statistical Analysis
Differences between groups were analyzed by Student’s t-test
for normally-distributed variables, by Mann–Whitney non-para-
metric independent sample test and by v2-test for categorical
variables, as appropriate.
Sensitivity, specificity, positive predictive value and negative
predictive value for HbA1c were calculated. Cohen’s kappa
coefficient was used to measure the level of agreement between
HbA1c and the diagnosis of diabetes or prediabetes by OGTT.
Data are expressed as means – standard deviation or SPSS
version 14.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Characteristics of the Study Cohort
A total of 1,054 participants were studied, 592 from the obesity
clinic cohort and 462 from the diabetes screening cohort.
The clinical characteristics of the two cohorts are shown in
Table 1. As expected, significant differences in all metabolic
and clinical parameters were observed between participants
recruited from the obesity clinic compared with those coming
from the diabetes screening program. To be noted, participants
from the obesity clinic had significantly lower age, higher
HbA1c, basal insulin and homeostatic model assessment of
insulin resistance (all P < 0.0001). In Table 1, values for lipid,
blood pressure and liver enzymes, available only for the obese
participants, are also shown. As the two cohorts differed signifi-
cantly in all parameters, we carried out the analyses in the two
groups separately.
In the obesity clinic cohort, after the OGTT (Table 2), 166
(28.0%) of the 592 participants were diagnosed with diabetes,
173 (29.3%) with prediabetes (IFG and/or IGT) and 253
(42.7%) had normal glucose tolerance (NGT). In this cohort,
173 (29.3%) of the 592 participants were diagnosed with predi-
abetes; 78 (13.2%) were IFG, 51 (8.6%) were IGT and 44
(7.4%) had both conditions. Using HbA1c for diagnosis, 140
(23.6%) of the participants had a value ≥6.5% (≥48 mmol/mol),
157 (26.57%) were within the prediabetes range (HbA1c 5.7–
6.4%, 39–46 mmol/mol) and 295 (49.8%) had values <5.7%
(<39 mmol/mol). Mean HbA1c levels were 7.7 – 1.8%,
5.8 – 0.7 and 5.4 – 0.5% in individuals diagnosed by OGTT as
diabetes mellitus (166), IFG/IGT (173), and NGT (253), respec-
tively.
In the diabetic screening cohort, after the OGTT (Table 2),
51 (11.0%) of the 462 participants were diagnosed with diabe-
tes, 300 (65.0%) with prediabetes (IFG and/or IGT) and 111
(24.0%) had normal glucose tolerance (NGT). Within the 300
(65.0%) of the 462 participants diagnosed with prediabetes, 171
(37.0%) were IFG, 29 (6.3%) were IGT and 100 (21.6%) had






AGE (years) 45.8 – 13.1 52.8 – 15.1 <0.0001
SEX (male/female) 180/412 165/297 0.070
BMI (kg/m2) 41.9 – 7.6 26.2 – 4.3 <0.0001
SBP (mmHg) 129.0 – 15.7 – –
DBP (mmHg) 82.9 – 10.5 – –
FPG (mg/dL) 113.5 – 47.9 107 – 20.7 0.003
2hPG (mg/dL) 136.1 – 48.7 132.5 – 46.2 0.023
HbA1c (%) 6.1 – 1.4 5.7 – 0.8 <0.0001
Insulin basal (lU/mol) 33 – 10.2 10.2 – 6.4 <0.0001
Insulin 120 (lU/mol) 103.5 – 63.5 70.5 – 54.6 <0.0001
HOMA-IR (U) 9.2 – 10.1 2.7 – 1.7 <0.0001
AST (U/L) 24.6 – 15.4 – –
ALT (U/L) 36.1 – 30.4 – –
TC (mg/dL) 203.7 – 42.6 – –
HDL-C (mg/dL) 47.9 – 12.6 – –
LDL-C (mg/dL) 126.5 – 36.1 – –
TG (mg/dL) 151.2 – 130.3 – –
Hypertensive 77.4% 37.5% <0.0001
Smokers* 69% – –
Physical activity 15.5% – –
2hPG, 2-h plasma glucose; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; BMI, body mass index; DBP, diastolic blood pressure;
FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; HDL-C,
high-density lipoprotein cholesterol; HOMA-IR, homeostatic model
assessment of insulin resistance; LDL-C, low-density lipoprotein choles-
terol; SBP, systolic blood pressure; TC, total cholesterol; TG, total triglyce-
rides. 2Data are expressed as mean – standard deviation. Differences
between groups were analyzed by Student’s t-test for normally-distrib-
uted variables and by Mann–Whitney U-test for non-parametric inde-
pendent samples. Categorical variables were analyzed by the v2-test.
*Smokers include current and former smokers. P-values <0.05 are
considered significant.
Table 2 | Prevalence of participants diagnosed by the oral glucose





DM 10 (19.6%) 21 (41.2%) 20 (39.2%) 51 (11.0%)
IFG/IGT 126 (42.0%) 144 (48.0%) 30 (10.0%) 300 (65.0%)
NGT 77 (69.4%) 33 (29.7%) 1 (0.9%) 111 (24.0%)
Total 213 (46.1%) 198 (42.9%) 51 (11.0%) 462
Obesity clinic cohort
OGTT
DM 17 (10.2%) 34 (20.5%) 115 (69.3%) 166 (28.0%)
IFG/IGT 89 (51.4%) 66 (38.2%) 18 (10.4%) 173 (29.3%)
NGT 189 (74.7%) 57 (22.5%) 7 (2.8%) 253 (42.7%)
Total 295 (49.8%) 157 (26.5%) 140 (23.6%) 592
DM, diabetes mellitus; HbA1c, glycated hemoglobin; IFG, impaired fast-
ing glucose; IGT, impaired glucose tolerance; OGTT, oral glucose toler-
ance test; NGT, normal glucose tolerance.
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both conditions. Using HbA1c for diagnosis, 51 (11.0%) of the
participants had a value ≥6.5% (≥48 mmol/mol), 198 (42.9%)
were within the prediabetes range (HbA1c 5.7–6.4%, 39–46
mmol/mol) and 213 (46.1%) had values <5.7% (<39 mmol/
mol). Mean HbA1c levels were 6.6 – 1.6%, 5.8 – 0.6 and
5.4 – 0.4% in individuals diagnosed by OGTT as diabetes mell-
itus (51), IFG/IGT (300) and NGT (111), respectively.
Agreement Between HbA1c and OGTT Results
In the obesity clinic cohort, HbA1c performed better for the
diagnosis of diabetes mellitus: 69.3% of the participants diag-
nosed as diabetic by OGTT had a HbA1c ≥6.5% (≥48 mmol/
mol). However, merely 38.2% of the prediabetic participants
by OGTT from the obesity clinic cohort had HbA1c between
5.7 and 6.4% (39–46 mmol/mol) (Table 2). It should be
pointed out that the obesity clinic cohort had a low preva-
lence of IFG/IGT (29.3%); a possible explanation could be that
these participants were relatively young, conceivably requiring
more time to develop glucose abnormalities. The normoglyce-
mic participants were well identified by HbA1c, with 74.7% of
NGT participants by OGTT having HbA1c <5.7%
(<39 mmol/mol). Agreement between HbA1c and diabetes
was good (Cohen’s j = 0.666), but was poor between HbA1c
and prediabetes (j = 0.202).
In the diabetic screening cohort, just 39.2% of the partici-
pants diagnosed as diabetic by OGTT had HbA1c ≥6.5%
(≥48 mmol/mol), and just 48% of the prediabetic participants
by OGTT had HbA1c between 5.7 and 6.4% (39–46 mmol/
mol; Table 2). In contrast, the normoglycemic participants were
well identified by HbA1c, with 69.4% of NGT participants by
OGTT having HbA1c <5.7% (<39 mmol/mol). Agreement
between HbA1c and diabetes was fair (j = 0.317), but was
poor between HbA1c and prediabetes (j = 0.187).
As HbA1c might reflect more post-glucose load values in the
prediabetic stage15, we evaluated the agreement between HbA1c
and each glycemic component of prediabetes. In the whole
population (obese and diabetes cohorts), the concordance was
very low with IGT (30%), intermediate with IFG (44.9%) and
higher with IFG + IGT (51.4%). The results were similar when
the two cohorts were individually analyzed (data not shown).
Sensitivity and Specificity of HbA1c for Diabetes and
Prediabetes
In the obesity clinic cohort, HbA1c ≥6.5% (≥48 mmol/mol) for
the diagnosis of diabetes, when compared with OGTT, showed
a sensitivity of 69.3% (95% confidence interval [CI] 61.7–
76.2%), with high specificity of 94.1% (95% CI 91.5–96.2%),
and good positive and negative predictive values (82.1 and
88.7%).
On the contrary, HbA1c between 5.7% (39 mmol/mol) and
6.4% (46 mmol/mol) did not identify prediabetic subjects well.
Sensitivity was just 39.1% (95% CI 31.1–47.5%), with a specific-
ity of 76.8% (95% CI 71.1–81.9%), and positive and negative
predictive values of 50.0 and 67.9%, respectively.
In the diabetes screening cohort, HbA1c ≥6.5% (≥48 mmol/
mol) for the diagnosis of diabetes showed very poor sensitivity
of 39.2% (95% CI 25.8–53.9%), with high specificity of 92.5%
(95% CI 89.5–94.8%), and positive and negative predictive
values of 39.2 and 92.5%, respectively.
Also, HbA1c between 5.7% (39 mmol/mol) and 6.4%
(46 mmol/mol) did not identify prediabetic subjects in this
cohort well. Sensitivity was just 53.3% (95% CI 47.2– 59.4%),
with a specificity of 70.0% (95% CI 60.5–78.4%), and positive
and negative predictive values of 81.4 and 37.9%, respectively.
Effect of Obesity on the Performance of HbA1c on the
Diagnosis of Diabetes and Prediabetes
As the obesity clinic cohort was selected by BMI criteria, we
aimed to assess the possible influence of bodyweight on glycemic
variables. Individuals were divided according to obesity class I–
III. In this cohort, 111 participants (18.8%) were classified as
class I obese (BMI 30–34.9 kg/m2), 150 (25.3%) as class II obese
(BMI 35–39.9 kg/m2) and 331 (55.9%) as class III obese (BMI
≥40 kg/m2). The mean ages were: class I 54 – 13 years, class II
46 – 14 years and class III 44 – 12 years.
In participants with class I obesity (n = 111), HbA1c
performed very well for the diagnosis of diabetes mellitus:
80.0% of the participants diagnosed as diabetic by OGTT had
HbA1c ≥6.5% (≥48 mmol/mol). As observed in the whole
obesity cohort, just 35.5% of the prediabetic participants with
class I obesity by OGTT had HbA1c between 5.7 and 6.4%
(39–46 mmol/mol). The normoglycemic participants were well
identified by HbA1c, with 75.6% of NGT patients by OGTT
having HbA1c <5.7% (<39 mmol/mol).
In participants belonging to class II and class III obesity, the
agreement between HbA1c and OGTT for the diagnosis of
diabetes was significantly lower (P < 0.005) than class I obese
participants; it was 58.3% for class II and 69.5% for class III
obesity. Again, the diagnosis for prediabetes by HbA1c was
inadequate, being just 44.7% for class II and 35.8% for class III
obesity, and this could be related to the decreasing age in each
BMI class I–III.
Phenotypic Characterization According to HbA1c Results
In our populations, we observed a high level of discordance
between results from HbA1c and OGTT, particularly when
analyzing data in the prediabetic range. In the whole population
of 1,054 participants, just 210 (44.4%) of the prediabetic
participants by OGTT had a concordant HbA1c of 5.7–6.4%
(39–46 mmol/mol). In contrast, 215 (45.5%) participants had a
positive OGTT for prediabetes, but had HbA1c within the
normal range. Finally, 266 (73.1%) of the participants had both
HbA1c and OGTT in the normal range. When the same analy-
ses were carried out in the two cohorts separately, the results
were very similar (data not shown).
We therefore examined the clinical and biochemical charac-
teristics of three groups (NGT concordant with both OGTT
and HbA1c, concordant for prediabetes with both OGTT and
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HbA1c, and discordant for prediabetes), aiming to identify pos-
sible factors that might help to select those at higher risk for
prediabetes that should be preferentially analyzed by OGTT.
As shown in Table 3, age increased significantly (all
P < 0.001) from participants with both OGTT and HbA1c in
the normal range, who were a mean age of 38 – 12 years, to
participants with a prediabetic OGTT, but a normal HbA1c
(mean age 49 – 15 years), to the participants with both tests in
the prediabetic range (mean age 55 – 12 years). Also, male sex
was more associated with having both tests in the prediabetic
diagnostic range. The homeostatic model assessment of insulin
resistance was, as expected, lower in the NGT group with both
tests compared with the others. Surprisingly, BMI was signifi-
cantly higher in the group that was NGT with both tests. This
could be explained by the fact that participants from the obesity
clinic cohort were significantly younger than the participants
recruited from the diabetes screening program. As, in our
whole cohort, altered glucose levels were associated with
increasing age, it follows that the younger obese participants
tended to cluster in the NGT group. In agreement with this
point, the obese participants in the Diabetes clinic cohort had a
65% prevalence of prediabetes, and had a mean age of
54 – 12 years. Multivariate linear regression confirmed the
independent association of increasing age, male sex and BMI
(data not shown). All other variables, including insulin, number
of hypertensive patients and number of smokers, were not
significantly different between the groups.
Finally, a worst lipid profile was significantly (P < 0.01) asso-
ciated with increasing age in the obesity clinic cohort, where
this data was available (data not shown).
DISCUSSION
The present study shows the poor agreement between HbA1c,
FPG and 2-h glucose post-OGTT for the diagnosis of
prediabetes in this Italian population. We observed that HbA1c
was inadequate to diagnose prediabetes in two different cohorts,
one characterized by the presence of only obese participants
and one representative of the general population undergoing a
screening for diabetes. Also, HbA1c performed quite badly in
the diagnosis of prediabetes compared with OGTT indepen-
dently of BMI. In particular, BMI obesity classes did not deter-
mine a change in performance of HbA1c, where only in the
35–40% of all cases HbA1c agreed with the diagnosis of predia-
betes made through the OGTT. The poor agreement between
HbA1c and OGTT for the diagnosis of prediabetes has been
reported in other studies in different populations8,9,13. The dif-
ferent pathophysiological mechanisms underlying abnormal glu-
cose homeostasis could explain the differences between HbA1c
and OGTT that were observed for the diagnosis of prediabetes.
Hepatic insulin resistance and defective early-phase insulin
secretion characterize IFG, resulting in the loss of control of
fasting hepatic glucose production. Instead, muscle insulin resis-
tance combined with defective late-phase insulin secretion, with
almost normal hepatic insulin sensitivity, characterizes IGT,
thus determining post-challenge hyperglycaemia16. Both IFG
and IGT show fast glucose changes; HbA1c, in contrast, repre-
sents the chronic exposure to both basal and postprandial
hyperglycemia over the previous 2–3 months. HbA1c, therefore,
could reflect a combination of the pathophysiological defects
underlying IFG and IGT over time. In fact, we observed the
highest concordance with HbA1c when the two conditions of
IFG + IGT were present together. These different pathophysio-
logical mechanisms might explain the discordant diagnoses of
prediabetes based on FPG, 2 hPG and HbA1c. However, when
overt diabetes develops, all the aforementioned underlying
mechanisms are operating, and this might explain the better
concordance that we observed between OGTT and HbA1c to
diagnose diabetes17–19. Accordingly, in the obesity clinic cohort,
the agreement between HbA1c and OGTT resulted much
better for diabetes, a condition that, in this population, HbA1c
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Age (years) 38 – 12 49 – 15 <0.001 55 – 12 <0.001 <0.001
Sex (male/female) 65/201 67/147 0.094 101/109 <0.001 <0.001
BMI (kg/m2) 36.2 – 9.1 31.9 – 9.2 <0.001 31.6 – 9.1 0.782 <0.001
Insulin basal (lU/mol) 24.8 – 16.9 25.4 – 22.7 0.787 28.8 – 24 0.280 0.730
Insulin 120 (lU/mol) 93.5 – 61.9 107.8 – 64.5 0.041 100.1 – 63.7 0.404 0.367
HOMA-IR (U) 5.2 – 3.7 6.4 – 5.7 0.335 7.4 – 6.0 0.210 0.008
Hypertensive 54% 52% 0.628 55% 0.493 0.800
Smokers* 65% 77% 0.131 68% 0.368 0.708
BMI, body mass index; HOMA-IR, homeostatic model assessment of insulin resistance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
Data are expressed as mean – standard deviation. Differences between groups were analyzed by Student’s t-test for normally-distributed variables,
by Mann–Whitney non-parametric independent sample-test and by v2-test for categorical variables, as appropriate. P-values <0.05 are considered
significant. *Smokers include current and former smokers. Group 1: participants with both oral glucose tolerance test (OGTT) and glycated hemo-
globin (HbA1c) in the normal glucose tolerance (NGT) range. Group 2: participants with OGTT in the prediabetes range and normal HbA1c. Group
3: participants with both OGTT and HbA1c in the prediabetes range.
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identifies with a sensitivity of 69.3%. Furthermore, 80% of the
participants with class I obesity that were diagnosed with diabe-
tes by the OGTT were identified by HbA1c ≥6.5% (≥48 mmol/
mol), suggesting that, in this category of subjects, HbA1c is a
very good marker of diabetes. HbA1c identified diabetic partici-
pants with class II and III obesity with less sensitivity. As
class II and class III participants were significantly younger
than class I obese participants, it could be speculated that they
might not have had the time to develop the chronic hypergly-
cemia that is necessary to affect HbA1c levels. Also, the patho-
physiological mechanisms that underlie severe obesity could
differ from those present in class I obesity20.
Finally, participants from the diabetes screening cohort, rep-
resentative of the general population undergoing screening for
diabetes mellitus, were not well identified as diabetic by HbA1c,
with just 39% of the diabetic participants diagnosed by OGTT
that were identified by HbA1c.
As pointed out by the American Diabetes Association1, the
characterization of subjects discordantly categorized by HbA1c
or OGTT is warranted, in order to identify variables that
could help to indicate the best possible test to be prescribed.
To this aim, we evaluated the phenotype of our participants
that were diagnosed as prediabetic by the OGTT, but were
not detected by HbA1c. The most significant variable that dif-
fered between participants discordantly categorized by HbA1c
and OGTT compared with participants concordant for NGT
or for prediabetes was their age (Table 3). Above the age of
55 years, participants were most likely to have both tests
above the diagnostic thresholds, whereas participants aged
<50 years were highly discordant, with just 32.6% of them
having HbA1c in the prediabetes range. Furthermore, male
sex was also significantly associated with having both HbA1c
and OGTT tests concordant for prediabetes. Thus, it might be
hypothesized that in male subjects above the age of 55 years,
HbA1c could be the test of choice for the diagnosis of predia-
betes; whereas in younger subjects, the use of the OGTT
might be preferable. Obviously, if possible, the combination of
more tests (for example HbA1c and FPG) might be the best
option, although less cost-effective, as previously shown by
other studies9.
The present study had some limitations. First, the cross-sec-
tional design of the study did not allow measuring long-term out-
comes. However, the present results are in line with other studies
that have found similar data in longitudinal observations9,21. Sec-
ond, our results are derived from single blood measurements,
reflecting standard clinical practice. Thus, individual and daily
changes in FPG and 2h post-OGTT glucose cannot be evaluated,
and this is a common limitation of most epidemiological studies.
Finally we did not look simultaneously for blood disorders, and
this might have carried over some cases of low hemoglobin levels
due to other causes. However, the present results are highly
consistent with other studies, suggesting that the prevalence of
hemoglobinopathies and of other blood disorders, if any present,
was not high enough to affect the final results.
In summary, we have shown that the agreement between
HbA1c, FPG and 2-h glucose post-OGTT for the diagnosis of
prediabetes was very poor in our two Italian cohorts. We have
also observed a relatively good agreement between HbA1c
≥6.5% (48 mmol/mol) and the diagnosis of diabetes.
For the first time, to our knowledge, we have shown that a
specific class of obesity positively influences the diagnostic per-
formance of HbA1c for the diagnosis of diabetes, which is
much better in class I obese subjects. However, when searching
for prediabetes, OGTT and HbA1c were persistently in poor
agreement. Finally, in class I obese subjects, we identified
specific characteristics, such as male sex and age >55 years, that
might help to ascertain subjects that are more likely to be
recognized as prediabetic with both tests, and in which the use
of HbA1c might be preferred over OGTT for economic and
practical reasons.
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